CA3011647A1 - Capsaicin sequential dosing method for treatment of morton's neuroma pain - Google Patents

Capsaicin sequential dosing method for treatment of morton's neuroma pain Download PDF

Info

Publication number
CA3011647A1
CA3011647A1 CA3011647A CA3011647A CA3011647A1 CA 3011647 A1 CA3011647 A1 CA 3011647A1 CA 3011647 A CA3011647 A CA 3011647A CA 3011647 A CA3011647 A CA 3011647A CA 3011647 A1 CA3011647 A1 CA 3011647A1
Authority
CA
Canada
Prior art keywords
capsaicin
dose
months
patient
neuroma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3011647A
Other languages
English (en)
French (fr)
Inventor
James N. Campbell
Peter D. Hanson
Randall Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centrexion Therapeutics Corp
Original Assignee
Centrexion Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centrexion Therapeutics Corp filed Critical Centrexion Therapeutics Corp
Publication of CA3011647A1 publication Critical patent/CA3011647A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3011647A 2016-01-22 2017-01-20 Capsaicin sequential dosing method for treatment of morton's neuroma pain Pending CA3011647A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281877P 2016-01-22 2016-01-22
US62/281,877 2016-01-22
PCT/US2017/014257 WO2017127628A1 (en) 2016-01-22 2017-01-20 Capsaicn sequential dosing method for treatment of morton's neuroma pain

Publications (1)

Publication Number Publication Date
CA3011647A1 true CA3011647A1 (en) 2017-07-27

Family

ID=59362242

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3011647A Pending CA3011647A1 (en) 2016-01-22 2017-01-20 Capsaicin sequential dosing method for treatment of morton's neuroma pain

Country Status (7)

Country Link
US (2) US20190022036A1 (enExample)
EP (1) EP3405187A4 (enExample)
JP (1) JP2019506397A (enExample)
CN (1) CN108697673A (enExample)
AU (1) AU2017210315A1 (enExample)
CA (1) CA3011647A1 (enExample)
WO (1) WO2017127628A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000490B2 (en) 2016-11-02 2021-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
WO2019018769A1 (en) 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE
EP3840739B1 (en) * 2018-08-24 2025-11-12 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of knee joint pain
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056305A2 (en) * 2002-12-18 2004-07-08 Algorx Administration of capsaicinoids
NZ540769A (en) * 2002-12-18 2009-03-31 Algorx Pharmaceuticals Inc Administration of capsaicinoids for the treatment of pain
KR101769010B1 (ko) * 2011-09-09 2017-08-17 비쭈리 헬스 사이언스 엘엘씨 Trpv1 선택적 작용제를 포함하는 통증 완화 조성물, 및 이의 제조방법 및 용도
US20140142073A1 (en) * 2012-11-12 2014-05-22 Api Genesis, Llc Aqueous based capsaicinoid formulations and methods of manufacture and use

Also Published As

Publication number Publication date
EP3405187A4 (en) 2019-07-31
US20190022036A1 (en) 2019-01-24
US20200297670A1 (en) 2020-09-24
WO2017127628A1 (en) 2017-07-27
EP3405187A1 (en) 2018-11-28
AU2017210315A1 (en) 2018-08-16
JP2019506397A (ja) 2019-03-07
CN108697673A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
US20200297670A1 (en) Capsaicin Sequential Dosing Method for Treatment of Morton's Neuroma Pain
US20250312298A1 (en) Methods and compositions for treatment of pain using capsaicin
EP2323645B1 (de) Verwendung niedrig-dosierter lokalanästhetika oder derivate davon zur therapie chronischer schmerzen, insbesondere migräne
Lipman Analgesic drugs for neuropathic and sympathetically maintained pain
US20210145772A1 (en) Capsaicinoids for use in treating acral lick granuloma
JP2020500915A (ja) 末梢神経障害性疼痛の治療に使用するための局所作用用フェニトイン
US20220265572A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
US20250241879A1 (en) Capsaicin sequential dosing method for treatment of knee joint pain
US20160101093A1 (en) Methods for the treatment of premature ejaculation
HK40031064A (en) Compositions and their use for treatment of pain using capsaicin
HK40031064B (en) Compositions and their use for treatment of pain using capsaicin
EP4704826A1 (en) Compositions and methods for treating post-traumatic stress disorder

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220111